Abivax pares gain after denying AstraZeneca speculation

Abivax pares gain after denying AstraZeneca speculation
Momentum traders are flagging several health care stocks that may be overheated heading into the new quarter. As of Feb. 18, 2026, elevated RSI readings suggest recent gains could be vulnerable to pullbacks despite strong headlines. AstraZeneca has surged roughly 14% over the https://t.co/eVMOTmA1TE
AstraZeneca profit climbs on cancer and heart drug demand
Walmart joins Nasdaq 100 on January 20, replacing AstraZeneca
AstraZeneca hails major breakthroughs with breast-cancer drugs
AstraZeneca to become latest drugmaker to strike deal with Trump. Its stock is down but outperforming the market.
290.6BUSD
タイプ
Common Stock
取引所
PINK
通貨コード
USD
通貨名
US Dollar
国名
USA
国のISOコード
US
ISIN
GB0009895292
CUSIP
-
セクター
Healthcare
業種
Drug Manufacturers - General
会計年度末
December
上場日
-
更新日時
-
PER
31.09
PEGレシオ
1.67
簿価
29.59
1株当たり配当金
3.13
配当利回り
1.70%
希薄化後1株当たり利益
6.03
ウォールストリートの目標株価
104.00
EPS見通し(現在の年度)
4.56
EPS見通し(次の年度)
5.06
EPS見通し(現在の四半期)
0
EPS見通し(次の四半期)
0
直近の四半期
-
売上高TTM
58,126,999,552
粗利益TTM
48,395,001,856
EBITDA
20,416,000,000
利益率
16.17%
総資産利益率TTM
9.06%
自己資本利益率TTM
21.67%
一株当たり売上高TTM
37.501
四半期売上高成長率(前年同期比)
12.00%
希薄化後EPS TTM
6.03
四半期利益成長率(前年同期比)
78.00%
トレーリングPER
31.09
フォワードPER
19
株価/売上高TTM
4.9994
株価/帳簿価格MRQ
6.1782
企業価値/売上高
5
企業価値/EBITDA
17
400.00
3.27%356.82
2.03%50.08
1.48%155.25
0.55%242.30
0.44%212.23
0.23%955.46
0.20%146.63
-5.33%393.19
-1.70%122.68
-0.41%